FDA Draft Guidance Covers New Discipline Review Letters Added by GDUFA II

Drug Industry Daily
A A
The FDA outlined how it will use information requests and the newly established discipline review letter — which originates from specialized staff concerning their portion of an ANDA review, such as bioequivalence, quality or labeling.

To View This Article:

Login

Subscribe To Drug Industry Daily